期刊
MOLECULAR CARCINOGENESIS
卷 58, 期 4, 页码 565-576出版社
WILEY
DOI: 10.1002/mc.22951
关键词
alantolactone; EGFR; inhibitor; pancreatic cancer; STAT3
资金
- National Key R&D Program of China [2017YFA0506000]
- National Natural Science Funding of China [81622043]
- Zhejiang Provincial Natural Science Foundation of China [LR16H310001, LY18H160047, LY17H160055]
- Medical Scientific Research Fund of Zhejiang Province [2019322308]
- Wenzhou science and technology project [Y20170280]
Several studies have implicated the feedback activation of signal transducer and activator of transcription 3 (STAT3) as a new cancer drug-resistance mechanism and linked it to the failure of epidermal growth factor receptor (EGFR)-targeted therapies. In this study, we discovered that Alantolactone, a natural sesquiterpene lactone, potently inhibited human pancreatic cancer cells and suppressed constitutively activated STAT3. In contrast, Alantolactone had little effect on the EGFR pathway. Moreover, combination of Alantolactone and an EGFR inhibitor, Erlotinib or Afatinib, demonstrated a remarkable synergistic anti-cancer effect against pancreatic cancer cells both in vitro and in vivo. Our results suggested that Alantolactone could sensitize human pancreatic cancer cells to EGFR inhibitors possibly through down-regulating the STAT3 signaling. Alantolactone, when combined with other EGFR targeted agents, could be further developed as a potential therapy for pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据